Riskpilot← Back to searchSign inGet full accessXNK Therapeutics AB
ABBankruptOrg 5568946601Research and experimental development on natural sciences and engineering · NACE 7210Est. 20120 employees
Revenue 2022
SEK 0
EBITDA margin
—
-118% vs 2021
Equity ratio
86.7%
Financial strength
Net profit 2022
SEK -74,6M
-116% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -74,2M | -118% |
| Net profit | SEK -74,6M | -116% |
| Total assets | SEK 94,1M | +122% |
| Equity | SEK 81,6M | +178% |
| Employees | 0 | — |
Legal name
XNK Therapeutics AB
Org number
5568946601
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
30 maj 2012
Share capital
SEK 1 419 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna eller en av dem i förening med Living, Johan Axel Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder Styrelsen ska bestå av 6 styrelseledamöter och 0 styrelsesuppleanter.
Company purpose
Aktiebolaget ska bedriva utveckling av nya teknologier för gen- och cellterapi, tillämpning av dessa teknologier i biomedicinsk forskning och medicinsk behandling samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 50 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −661 | −3 087 | −8 205 | −33 967 | −74 153 |
| Depreciation & amort. | −9 | −30 | −304 | −582 | −858 |
| EBIT | −670 | −3 117 | −8 509 | −34 549 | −75 011 |
| Net financials | — | −535 | −293 | — | 400 |
| Profit before tax | −671 | −3 668 | −8 803 | −34 549 | −74 611 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −671 | −3 668 | −8 803 | −34 549 | −74 611 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 953 | 4 518 | 7 025 | 42 333 | 94 090 |
| Equity | −267 | 1 427 | 3 560 | 29 331 | 81 567 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 220 | 2 811 | 2 133 | 11 906 | 11 805 |
| Total debt | 1 220 | 2 811 | 2 133 | 11 906 | 11 805 |
EBITDA margin
-7415300000.0%
This company
15.8%
Market median
-46932278581% vs market
20182022
Equity ratio
86.7%
This company
38.2%
Market median
+127% vs market
20182022
Return on equity
-91.5%
This company
18.4%
Market median
-597% vs market
20182022
Net profit margin
-7461100000.0%
This company
8.1%
Market median
-92112345779% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
0.15×
This company
0.62×
Market median
+76% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
JA Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (2) | ||
KM Chief Executive Officer | Chief Executive Officer | 2020 – 2020 |
KL Chief Auditor | Chief Auditor | 2021 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2020 | |
| Chairman | 2022 | |
| Board of Directors | 2020 | |
| Former (2) | ||
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2020 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of XNK Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karin Marie Mellström | Chief Executive Officer | 0 companies |
| Johan Axel Living | Chief Executive Officer | 0 companies |
| Karl Leonard Daun | Chief Auditor | 0 companies |
| Stephen James Wooding | Board of Directors | 0 companies |
| Karl David Berglund | Board of Directors | 0 companies |
| Ted Ingemar Jakob Fjällman | Board of Directors | 0 companies |
| Eva Agneta Edberg | Board of Directors | 0 companies |
| Lena Birgitta Degling Wikingsson | Board of Directors | 0 companies |
| Nils Gunnar Mattsson | Chairman | 0 companies |
| Hans-Gustaf Einar Ljunggren | Board of Directors | 0 companies |